Home
overview
The cloning of the genome presents huge opportunities for the pharmaceutical industry to discover new targets for the therapeutics of the future. This bodes well for future drug pipelines in the industry but raises the problem of identifying the best targets to develop out of the large number being identified. The issue of assigning some therapeutic value to newly discovered genes is also becoming increasingly important to ensure that patents for genes can be obtained. This conference will explore the latest issues in the field from technological advances to new applications of more traditional methods of target validation. Validation strategies employed by some of the biggest companies in the world will be discussed with a focus on the overall approaches rather than the technology itself. It is a must for those involved in drug research and discovery if you want to stay abreast of developments in the field.

Innovations in Target Validation is organised and produced by SMi: we specialise in providing senior executives with timely, strategic and focused up to date information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry and government figures and seek their advice and opinions.

Please register now to guarantee your place at this important conference.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Prof William Shaw

Prof William Shaw, Chief Scientific Officer, PanTherix

9:10 RECENT DEVELOPMENTS IN TARGET VALIDATION TECHNOLOGY

Dr Deborah Baly

Dr Deborah Baly, Director, Cell and Analytical Biology, Bayer

  • Target validation in in vivo models: slow and expensive or worth the effort?
  • Cloning the genome and the impact on target validation
  • IP issues and demonstrating utility of cloned genes
  • Molecular Pathology: a useful approach to target validation?
  • Functional genomics: is this the future for target validation?
  • Identifying the function of the gene: what next?
  • 9:40 THE DISCOVERY AND VALIDATION OF NEW DRUG TARGETS TO FIND THE R&D PIPELINE

    Prof Graham Boulnois

    Prof Graham Boulnois, Senior Vice President, Global Lead Innovation, Global Lead Innovation, Aventis

  • Exploiting the human genome
  • Technology platforms and organisation approach to target validation
  • Building a high throughput target validation capability
  • Target selection and initiation of drug hunting projects
  • 10:20 FROM DRUG TO TARGET

    Dr Mark Cockett

    Dr Mark Cockett, Executive Director, Functional Genomics, Bristol Myers Squibb

  • Serendipity vs scientific enquiry: the revolution bought about by genomic technologies
  • How can genomic technologies be applied to determine mechanism of action of compounds?
  • To what extend can knowledge of the mechanism of action be applied to the validation of new targets?
  • Mining compound libraries for new targets using this technology
  • Possibility of using genomic technology to expand indications for marketed products.
  • 11:00 Morning coffee

    11:20 A UNIFIED APPROACH TO TARGET VALIDATION

    Simon Beaulah

    Simon Beaulah, Product Manager, Synomics

  • Combining disparate data formats to provide a unified interface
  • Using relationships between data to make new insights
  • Improving collaboration within project teams
  • 12:00 TISSUE PROFILING TO IDENTIFY TARGETS

    Dr Andrew Eisen

    Dr Andrew Eisen, Project Leader Metabolic Diseases, CuraGen

  • High throughput genomics to identify targets for drug development
  • Refined choices utilising a combination of genetics, diseased tissue and drug response
  • Validation and the choice for development
  • Case studies: successes at CuraGen
  • 12:40 Lunch

    13:40 SIMPLE ORGANISMS AS MODELS

    Dr David Matthews

    Dr David Matthews, Associate Director, Drug Discovery, Exelixis

  • Model organism genetics in the post-genomic era
  • Genetic approaches to discovery of novel drug targets
  • Applying knowledge of simple organisms to human disease
  • Time and costs involved in ‘traditional’ genetic approaches
  • Comparison to other methods of determining gene function: costs, accuracy and speed
  • 14:20 TRANSGENIC APPROACHES

    Dr Kazimierz Babinski

    Dr Kazimierz Babinski, President & CEO, Antalium

  • The therapeutic potential of targeting ion channels
  • Using genomic approaches to identify new ion channel targets
  • Applying transgenic approaches to target validation: how & why?
  • Developing transgenic mice into animal models for drug research
  • Cost & time vs accuracy: how do transgenic approaches compare to other, quicker methods of target validation?
  • 15:00 METABOLIC DISEASE TARGET VALIDATION

    Dr Patricia Kilian

    Dr Patricia Kilian, Vice President, Research, Metabolic Diseases, Pharmacia

  • Database mining
  • Model organisms for discovery novel targets
  • Target validation
  • Pathways as entry points
  • 15:40 Afternoon tea

    16:00 Antibodies for drug target validation

    Dr Dominik Escher

    Dr Dominik Escher, Chief Executive Officer, ESBATech

  • Antibodies as novel tool for target validation
  • Using the specificity and high affinity of antibodies for target validation
  • Overcoming the problem of intracellular conditions for antibodies
  • Functional protein domain knockout of target by intracellular expression of specific antibodies
  • In vivo validation model
  • 16:30 TARGET VALIDATION USING FOLD RECOGNITION

    Dr Ben Hitz

    Dr Ben Hitz, Scientific Applications Manager, Proceryon

  • The old adage ‘structure relates to function’ and applications in the era of the genome
  • Overcoming the difficulties in determining protein structure
  • Strategies to get from amino acid sequence to functional information
  • Using fold recognition to speed up the pace of lead identification
  • 17:00 DESIGN AND CREATION OF GENETICALLY MODIFIED RODENTS, CURRENT AND FUTURE EVOLUTIONS FOR DRUG TARGET VALIDATION

    Kader Thiam

    Kader Thiam, Scientific Sales Manager, Genoway

  • Cutting-edge techniques available for the generation of transgenic mice and rats
  • Development of conditional and inducible systems
  • Comparative analysis of the scientific risks and limitations linked to these new technologies
  • Innovative strategies for drug target validation in tailor-made animal models
  • 17:30 Chairman’s Closing Remarks and Close of Day One

    17:40 Networking Drinks Reception

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Juergen Hammer

    Dr Juergen Hammer, Research Leader, Head of Genomics Section, Hoffman-La Roche

    9:10 INDENTIFYING TARGETS IN HUMAN TISSUE

    Dr Julian Beesley

    Dr Julian Beesley, European Sales Director, LifeSpan Biosciences

  • Why use human tissue to identify and validate new drug targets?
  • The physiological and pharmacological significance of GPCRs
  • Techniques being applied in the identification of GPCRs in normal and diseased tissue
  • Targets identified and validated to date using this technology
  • Commercial opportunities in the development of a comprehensive GPCR database
  • 9:40 ANTISENSE TECHNOLOGY AND TARGET VALIDATION

    Dr Frank Bennett

    Dr Frank Bennett, Vice President, Antisense Research, Isis

  • Advances in antisense technology
  • The attributes of using antisense technology in the search for gene function and validating novel genes
  • Use of antisense oligonucleotide libraries to identify novel functions of genes
  • From gene to man: validation of novel genes using antisense technology
  • 10:20 VALIDATION OF DRUG TARGETS IN COMMONE DISEASE USING HUMAN POPULATIONS

    Dr Patrick Kleyn

    Dr Patrick Kleyn, Chief Scientific Officer, Gemini Genomics

  • The application of human genomics for drug target validation
  • Association between gene-based single nucleotide polymorphisms (SNPs) and disease
  • Discovery of relevance of genes in multiple therapeutic areas
  • Dissection of complex diseases into underlying risk traits enables more informed assessment of therapeutic potential for drug targets
  • 11:00 Morning coffee

    11:20 VALIDATING CANCER TARGETS

    Dr Bruce Roberts

    Dr Bruce Roberts, Vice President, Applied Genomics, Genzyme Molecular Oncology

  • The promise and challenge of cancer vaccines
  • The importance of potent tumour antigens in cancer vaccines
  • Accelerating antigen discovery by combining functional and genomic technologies
  • Incorporating validation into the discovery process
  • Antigen validation: in vitro and in vivo models
  • Clinical evaluation and product prioritisation
  • 12:00 TARGET DISCOVERY AND VALIDATION IN CANCER RESEARCH

    Dr Ying Luo

    Dr Ying Luo, Senior Director, Genomics and Target Discovery, Rigel

  • Using retroviral probes to identify targets
  • Developing knowledge of a target to discover other or better targets in the signalling pathway
  • Development of high throughput validation assays to speed up the pace of validation of targets
  • The role for proteomics in target validation technology
  • Effective partnerships in target validation: Janssen & Rigel
  • 12:40 Lunch

    13:40 VALIDATING ANTIGENIC TARGETS

    Dr Aya Jakobovits

    Dr Aya Jakobovits, Vice President, Research & CSO, UroGenesys

  • Discovery and validation of PSCA
  • PSCA validation as a target for antibody therapy in prostrate cancer
  • PSCA as a valid target for other cancers
  • Application of xenograft models in target validation
  • Future development prospects and corporate partnerships
  • 14:20 TARGET IDENTIFICATION AND VLIADATION USING A FUNCTIONAL PROTEOMICS APPROACH

    Dr Jasbinder Sanghera

    Dr Jasbinder Sanghera, Vice President, Drug Discovery, Kinetek

  • Why target protein kinases?
  • How is KineomicsTM used to discover and validate targets?
  • KinemoicsTM is a versatile tool integrating target discovery with lead optimisation
  • What are the advantages to other identification and validation methodologies?
  • 15:00 PROTEOMICS & TARGET VALIDATION

    Dr Bassil Dahiyat

    Dr Bassil Dahiyat, President & CEO, Xencor

  • Overview of the technology involved in proteome analysis
  • Bioinformatic requirements for effective proteome analysis
  • How can proteome data be used to validate targets: methods at Xencor
  • Cost vs results: is proteomics a cost-effective method of validating targets?
  • Future advances: integrating genomic and proteomic information effectively
  • 15:40 Afternoon Tea

    16:00 GENE EXPRESSION ARRAYS

    Adesh Kaul

    Adesh Kaul, Marketing Manager, Genedata

  • The revolution in gene and protein expression analysis through High-throughput technologies
  • Standardized procedures to enable reliable and reproducible results
  • Monitoring data quality using Gene Data's proprietary analysis tools
  • Sharing information on a company-wide scale through effective software tools
  • Functional analysis of gene expression and genomics data leading to identification of new drug targets
  • Using the Gene Data software to predict toxicity early in the development process
  • 16:30 EVIDENCE-BASED TARGET VALIDATION

    Dr Uli Hacksell

    Dr Uli Hacksell, Executive Vice President, Drug Discovery, ACADIA

  • Leveraging existing clinical knowledge to identify new targets
  • Applying functional genomics to clinical knowledge in order to expand the number of potential targets
  • Validating new targets by comparisons to existing therapeutics
  • Overview of the methods used to identify a new antipsychotic target
  • Commercial viability of gene specific treatments
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Lessons to be Learned from Start Up Companies: An Interactive Workshop
    Workshop

    Lessons to be Learned from Start Up Companies: An Interactive Workshop

    The Hatton, at etc. venues
    9th February 2001
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.